Financial Disclosures是个好东西，但也需要作者自己的诚实。
JAMA，the Journal of the American Medical Association (impact factor, 24.831),是临床的顶极杂志。在上面发表文摘的都是临床各个专业的牛人。
随便找了几个最近这个杂志发表的atilce，请各位看客仔细看一下Financial Disclosures，或许国外的月亮一定会更圆。
Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression
http://jama.ama-assn.org/cgi/content/full/299/8/901
Financial Disclosures: Dr Asarnow reports consulting on cognitive behavioral therapy and cognitive behavioral therapy for depression supported by an unrestricted grant from Pfizer and has funding from Philip Morris; a family member has funding from Bristol-Myers Squibb and has consulted for Roche. Dr Birmaher reports participating in forums sponsored by Solvay Pharmaceuticals Inc and Abcomm Inc; presented on bipolar disorders in children at a meeting sponsored by Solvay; and reports receiving royalties from Random House Inc. Dr Emslie reports receiving research support from Eli Lilly, Organon, Shire, Somerset, Forest Laboratories, and Biobehavioral Diagnostics Inc; consults for Eli Lilly, GlaxoSmithKline, Wyeth-Ayerst, Shire, and Biobehavioral Diagnostics Inc; and is on the speaker's bureau for McNeil. Dr Hughes reports being a consultant for Biobehavioral Diagnostics, Inc. Dr Keller reported research support from Pfizer; and consults for CENEREX, Cephalon, Cypress Bioscience, Cyberonics, Forest Laboratories, Janssen, JDS, Organon, Novartis, Pfizer, and Wyeth. Dr Keller reports serving on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, CENEREX, Cyberonics, Cypress Bioscience, Forest Laboratories, Janssen, Novartis, Organon, and Pfizer. Dr McCracken reports receiving research support from Eli Lilly, McNeil, Bristol-Myers Squibb, and Shire; and consults for Shire, Eli Lilly, McNeil, Pfizer, Janssen, Johnson & Johnson, Novartis and Wyeth. Dr Melhem reports receiving the AFSP-Pfizer travel award to present at the American Association of Suicidology annual meeting in New Orleans, Louisiana. Dr Wagner reports past research support from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, Novartis, Organon, Pfizer, and Wyeth-Ayerst; and is a consultant/advisory board member for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Novartis, Ortho-McNeil, Pfizer, Organon, Otsuka, Solvay, UCB Pharma, Wyeth Ayerst. No other financial disclosures were reported.
Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk
Vol. 299 No. 11, March 19, 2008
http://jama.ama-assn.org/cgi/content/full/299/8/901
Financial Disclosures: Dr Nicholls reports that he has received speaking honoraria from Pfizer, AstraZeneca, Merck, Schering-Plough, and Takeda and consulting fees from Roche, AstraZeneca, Pfizer, and Novo-Nordisk. Dr Ellis reports that he is named as coinventor on pending patents filed by the Cleveland Clinic referring to use of genetic markers in cardiovascular disease. Dr Ellis also reports that he has received research support from Lilly, Centocor, Boston Scientific, and Cardlodx and has received consulting fees from Celera, Cordis, Boston Scientific, and Abbott Vascular. Dr Allayee reports that he is named as coinventor on pending and approved patents filed by the University of California that are related to identification of 5-lipoxygenase as a gene involved in cardiovascular- and diabetes-related traits. Dr Allayee also reports that he has received honoraria/consulting fees from Reliant Pharmaceuticals and Corautus Genetics. Dr Lusis reports that he has received research grant support from Merck, Anthera, and Bristol-Myers Squibb. Dr Hazen reports that he is named as coinventor on pending and approved patents filed by the Cleveland Clinic that refer to the use of biomarkers to inflammatory and cardiovascular diseases. Dr Hazen also reports that he is the scientific founder of PrognostiX Inc; has received research grant support from Abbott Diagnostics, Pfizer, Merck, PrognostiX Inc, Hawaii Biotech, ArgiNOx, Sanofi, and Takeda; and has received honoraria and consulting fees from Abbott Diagnostics, BioSite, Merck, Lilly, Pfizer, PrognostiX Inc, Wyeth, BioPhysical, and AstraZeneca. No other disclosures were reported.
Large-Scale Analysis of Association Between LRP5 and LRP6 Variants and Osteoporosis
Vol. 299 No. 11, March 19, 2008
http://jama.ama-assn.org/cgi/content/full/299/11/1277
Financial Disclosures: Dr Ralston reported receiving consultancies from Novartis, Proctor & Gamble, and Sanofi-Aventis; serving as a lecturer at meetings sponsored by Merck, GlaxoSmithKline, Roche, Novartis, Proctor & Gamble, Sanofi-Aventis, and Servier; and receiving research grants from Novartis, Proctor & Gamble, and Wyeth. Dr Brixen reported serving on the advisory boards of Eli Lilly, Nycomed, Servier, Novartis, and Amgen and on the speakers bureau of Servier; and conducting clinical trials for Eli Lilly, Novartis, and Osteologix. Dr Langdahl reported serving on the advisory boards of Eli Lilly, Nycomed, Servier, Novartis, and Amgen and on the speakers bureau of Roche; and conducting clinical trials for Pfizer. No other disclosures were reported. GENOMOS is supported by the reported European Union grant and the specific teams that participated have additional grants as specified herein; these grants have been used for funding largely personnel salaries and laboratory expenses. None of the additional investigators or study group members listed below received compensation for services involving preparation or writing of the manuscript.